The Effectiveness of Oral Acyclovir in the Treatment of Molluscum Contagiosum in Children

NCT ID: NCT04476186

Last Updated: 2020-07-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

35 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-06-15

Study Completion Date

2021-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators will study the effectiveness of acyclovir in the treatment of molluscum contagiosum in assiut university hospital - dermatological out patient clinic the treatment group will receive acyclovir 200 mg 5 times per day the controlled group will receive local KOH solution

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study population:

Site of the study: The outpatient dermatological clinic in Assiut university hospital.

Participants: children (2 -16) years' old attending dermatological clinic in Assiut university hospital and their parents.

Methodology in details:

1. We will use the social media as " Facebook" to invite patient to visit the clinic and follow up them due to the protective measures of covid 19.
2. Diagnosis of the patient with molluscum contagiosum according to the clinical picture
3. Collecting data including personal and clinical data through interviewing the patient and his or her parents
4. Pictures of the lesions will be taken before and after treatment after patient consent.
5. We will Randomly assigning the patient to either treatment group or controlled group according to simple random table
6. Prescribing the treatment according to the patient group
7. Follow up of the patient after 1 weak and each week according to the response to treatment or presence of complication

Inclusion criteria:

Children (5 -15) years old with Molluscum contagiosum.

Exclusion criteria:

1. Molluscum contagiosum with Inflamed spot
2. Known immune compromised children
3. Molluscum lesion in the eye lid.
4. Children with renal impairment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Molluscum Contagiosum

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

treatment group

200 mg of oral acyclovir 5 timed per day for 5 days per week for maximum 1 month

Group Type ACTIVE_COMPARATOR

Acyclovir

Intervention Type DRUG

oral syrp

controlled group

KOH 10 % solution local application with apiece of cotton 2 time per day maximum for 1 month

Group Type PLACEBO_COMPARATOR

KOH 10 %

Intervention Type DRUG

solution for local application

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Acyclovir

oral syrp

Intervention Type DRUG

KOH 10 %

solution for local application

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Zovirax - Acyclovir KOH

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Children (2 -16) years old with Molluscum contagiosum.

Exclusion Criteria

* Molluscum contagiosum with Inflamed spot Known immune compromised children Molluscum lesion in the eye lid. Children with renal impairment.
Minimum Eligible Age

2 Years

Maximum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

assistant professor Ghada M. Khafagy

UNKNOWN

Sponsor Role collaborator

Dr. Marwa Diaaeldeen Abbass Hasan

UNKNOWN

Sponsor Role collaborator

Prof. Dr. Emad Taha Abd-Elahim Ebiad

UNKNOWN

Sponsor Role collaborator

Dalia Mahran

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dalia Mahran

professor of public health and community medicine

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ghada Mahmoud, Assist Prof

Role: PRINCIPAL_INVESTIGATOR

Cairo University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hamdy Gomaa

Asyut, New Assiut City, Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Hamdy Gomaa

Role: CONTACT

00201000882184

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Hamdy Gomaa

Role: primary

00201000882184

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

site of study assiut U H

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.